Engineered immune cells take on lupus and arthritis in new trial
NCT ID NCT07246096
First seen Nov 25, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This early-stage study is testing a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like lupus, scleroderma, and rheumatoid arthritis that haven't responded to standard therapies. The treatment uses specially engineered immune cells to target and potentially reset the faulty immune system. The study will enroll 60 adults and focus on safety and how well the therapy controls the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.